Literature DB >> 29183866

An optimized whole blood assay measuring expression and activity of NLRP3, NLRC4 and AIM2 inflammasomes.

Lev Grinstein1, Kristin Endter1, Christian M Hedrich2, Sören Reinke1, Hella Luksch1, Felix Schulze1, Avril A B Robertson3, Matthew A Cooper3, Angela Rösen-Wolff1, Stefan Winkler4.   

Abstract

The proinflammatory protease caspase-1 plays pivotal roles in central pathways of innate immunity, thereby contributing to pathogen clearance. Beside its physiological role, dysregulated activity of caspase-1 is known to contribute to an increasing number of diseases. In this study, we optimized and validated a low-volume human whole blood assay facilitating the measurement of caspase-1 activation and inflammasome-related gene expression upon stimulation of the NLRP3, NLRC4 or AIM2 inflammasome. Using the NLRP3 inflammasome specific inhibitor MCC950, we were able to measure the activity of canonical or alternative NLRP3 pathways, AIM2 and NLRC4 inflammasomes in whole blood. Based on our data we assume a superposition of NLRP3 and NLRC4 inflammasome activities in human whole blood following stimulation with S. typhimurium. The optimized whole blood assay may be suitable for diagnostic and research purposes for pediatric patients who can only donate small amounts of blood.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AIM2; Inflammasome; NLRC4; NLRP3; Procaspase-1; Whole blood assay

Mesh:

Substances:

Year:  2017        PMID: 29183866     DOI: 10.1016/j.clim.2017.11.011

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  3 in total

1.  Validation of reference genes for whole blood gene expression analysis in cord blood of preterm and full-term neonates and peripheral blood of healthy adults.

Authors:  Kristin Hieronymus; Benjamin Dorschner; Felix Schulze; Neeta L Vora; Joel S Parker; Jennifer Lucia Winkler; Angela Rösen-Wolff; Stefan Winkler
Journal:  BMC Genomics       Date:  2021-06-30       Impact factor: 3.969

2.  MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.

Authors:  Lieselotte Vande Walle; Irma B Stowe; Pavel Šácha; Bettina L Lee; Dieter Demon; Amelie Fossoul; Filip Van Hauwermeiren; Pedro H V Saavedra; Petr Šimon; Vladimír Šubrt; Libor Kostka; Craig E Stivala; Victoria C Pham; Steven T Staben; Sayumi Yamazoe; Jan Konvalinka; Nobuhiko Kayagaki; Mohamed Lamkanfi
Journal:  PLoS Biol       Date:  2019-09-16       Impact factor: 8.029

3.  Inflammasome in ALS Skeletal Muscle: NLRP3 as a Potential Biomarker.

Authors:  Leticia Moreno-García; Francisco J Miana-Mena; Laura Moreno-Martínez; Miriam de la Torre; Christian Lunetta; Claudia Tarlarini; Pilar Zaragoza; Ana Cristina Calvo; Rosario Osta
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.